{"user":{"works":[{"shortdoi":"dmf","published":"2011-06-01T00:00:00+02:00","mendeley":null,"updated_at":"1969-12-31T16:00:00-08:00","mas":48080893,"pub_med_central":null,"citations_count":0,"title":"Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients","doi":"10.1007/s00345-010-0642-3","year":2011,"pub_med":"21258806"},{"shortdoi":"dvpb63","published":null,"mendeley":null,"updated_at":"1969-12-31T16:00:00-08:00","mas":49470307,"pub_med_central":null,"citations_count":0,"title":"7053 POSTER Hormonal Impact of Second-line Salvage Chemotherapy With Carboplatin Plus Weekly Docetaxel in Patients With Castration and Docetaxel-resistant Prostate Cancer","doi":"10.1016/S0959-8049(11)72004-4","year":2011,"pub_med":null},{"shortdoi":"dvpb63","published":null,"mendeley":null,"updated_at":"1969-12-31T16:00:00-08:00","mas":49470307,"pub_med_central":null,"citations_count":0,"title":"7053 POSTER Hormonal Impact of Second-line Salvage Chemotherapy With Carboplatin Plus Weekly Docetaxel in Patients With Castration and Docetaxel-resistant Prostate Cancer","doi":"10.1016/S0959-8049(11)72004-4","year":2011,"pub_med":null},{"shortdoi":"djq","published":"2010-06-01T00:00:00+02:00","mendeley":null,"updated_at":"2011-09-27T12:59:42-07:00","mas":29760453,"pub_med_central":null,"citations_count":9,"title":"Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer","doi":"10.1007/s00345-010-0527-5","year":2010,"pub_med":"20229232"},{"shortdoi":"dmh","published":null,"mendeley":null,"updated_at":"1969-12-31T16:00:00-08:00","mas":47695270,"pub_med_central":null,"citations_count":1,"title":"New Systemic Therapies for Refractory Tumors","doi":"10.1007/978-1-84800-370-5_18","year":2010,"pub_med":null},{"shortdoi":"djd","published":"2009-01-01T00:00:00+01:00","mendeley":null,"updated_at":"2011-09-27T12:59:41-07:00","mas":31265045,"pub_med_central":null,"citations_count":0,"title":"Complete cytogenetic remission after decitabine treatment in a patient with secondary AML harbouring high p15 INK4b gene methylation and high global DNA methylation","doi":"10.1007/s00277-008-0584-7","year":2008,"pub_med":"18704418"},{"shortdoi":"djp","published":null,"mendeley":null,"updated_at":"1969-12-31T16:00:00-08:00","mas":31485994,"pub_med_central":null,"citations_count":0,"title":"P59 High efficacy of carboplatin (C) plus weekly docetaxel (D) as second-line treatment for docetaxel-resistant, hormone-refractory prostate cancer (HRPC)","doi":"10.1016/S1040-8428(09)70097-6","year":2009,"pub_med":null},{"shortdoi":"dmm","published":null,"mendeley":null,"updated_at":"1969-12-31T16:00:00-08:00","mas":32596615,"pub_med_central":null,"citations_count":0,"title":"7150 Response of renal lesions in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib \u2013 a single center retrospective analysis","doi":"10.1016/S1359-6349(09)71483-1","year":2009,"pub_med":null},{"shortdoi":"dmn","published":null,"mendeley":null,"updated_at":"1969-12-31T16:00:00-08:00","mas":32594946,"pub_med_central":null,"citations_count":0,"title":"7046 Effectiveness of Carboplatin (C) plus weekly docetaxel (D) as second-line treatment for docetaxel-resistant, hormone-refractory prostate cancer (HRPC)","doi":"10.1016/S1359-6349(09)71424-7","year":2009,"pub_med":null},{"shortdoi":"dh7","published":"2008-11-01T00:00:00+01:00","mendeley":null,"updated_at":"1969-12-31T16:00:00-08:00","mas":32385223,"pub_med_central":null,"citations_count":13,"title":"Erythropoietin in cancer-related anemia","doi":"10.1097/CCO.0b013e3283136971","year":2008,"pub_med":"18841051"},{"shortdoi":"dmr","published":"2008-04-01T00:00:00+02:00","mendeley":null,"updated_at":"2011-09-27T13:02:33-07:00","mas":38802169,"pub_med_central":null,"citations_count":19,"title":"Targeted therapies for patients with germ cell tumors","doi":"10.1517/13543784.17.4.511","year":2008,"pub_med":"18363516"},{"shortdoi":"dd3","published":"2008-03-06T00:00:00+01:00","mendeley":"cdeaed70-6cff-11df-a2b2-0026b95e3eb7","updated_at":"2011-09-27T13:00:11-07:00","mas":14905504,"pub_med_central":null,"citations_count":4,"title":"Duplication: stop favouring applicant with longest list","doi":"10.1038/452029a","year":2008,"pub_med":"18322509"},{"shortdoi":"djf","published":null,"mendeley":null,"updated_at":"1969-12-31T16:00:00-08:00","mas":32541175,"pub_med_central":null,"citations_count":0,"title":"61 POSTER Contrast enhanced perfusion CT (CEPCT) predicts early response of sunitinib in renal cell carcinoma (RCC) patients","doi":"10.1016/S1359-6349(08)71993-1","year":2008,"pub_med":null},{"shortdoi":"dmw","published":null,"mendeley":"f38c0c60-0798-11e0-81fb-0024e8453de6","updated_at":"2011-09-27T12:59:21-07:00","mas":34296600,"pub_med_central":null,"citations_count":4,"title":"Blogs, Wikis und Podcasts im Unterricht","doi":"10.1002/biuz.200890080","year":2008,"pub_med":null},{"shortdoi":"dhw","published":"2005-06-01T00:00:00+02:00","mendeley":null,"updated_at":"2011-09-27T13:02:33-07:00","mas":38801725,"pub_med_central":null,"citations_count":96,"title":"Peroxisome proliferator-activated receptor-? ligands for the treatment of breast cancer","doi":"10.1517/13543784.14.6.557","year":2005,"pub_med":"16004588"},{"shortdoi":"bshzzj","published":"2004-04-01T00:00:00+02:00","mendeley":null,"updated_at":"1969-12-31T16:00:00-08:00","mas":33374590,"pub_med_central":null,"citations_count":46,"title":"Peroxisome proliferator-activated receptor ? ligands induce growth inhibition and apoptosis of human B lymphocytic leukemia","doi":"10.1016/j.leukres.2003.07.005","year":2004,"pub_med":null},{"shortdoi":"bshzzj","published":"2004-04-01T00:00:00+02:00","mendeley":null,"updated_at":"1969-12-31T16:00:00-08:00","mas":33374590,"pub_med_central":null,"citations_count":46,"title":"Peroxisome proliferator-activated receptor ? ligands induce growth inhibition and apoptosis of human B lymphocytic leukemia","doi":"10.1016/j.leukres.2003.07.005","year":2004,"pub_med":null},{"shortdoi":"dhg","published":"2003-11-01T00:00:00+01:00","mendeley":null,"updated_at":"1969-12-31T16:00:00-08:00","mas":32023297,"pub_med_central":null,"citations_count":65,"title":"Ligands for PPAR? and RAR Cause Induction of Growth Inhibition and Apoptosis in Human Glioblastomas","doi":"10.1023/B:NEON.0000003728.80052.a8","year":2003,"pub_med":null},{"shortdoi":"dm2","published":"2003-05-01T00:00:00+02:00","mendeley":null,"updated_at":"1969-12-31T16:00:00-08:00","mas":47711268,"pub_med_central":null,"citations_count":96,"title":"PPAR? Ligands and ATRA Inhibit the Invasion of Human Breast Cancer Cells in vitro","doi":"10.1023/A:1023366117157","year":2003,"pub_med":null},{"shortdoi":"dhh","published":"2002-12-01T00:00:00+01:00","mendeley":null,"updated_at":"2011-09-27T13:01:53-07:00","mas":31779945,"pub_med_central":null,"citations_count":46,"title":"Chemotherapy for Breast Cancer Brain Metastases","doi":"10.1159/000067443","year":2002,"pub_med":null},{"shortdoi":"djk","published":"2002-08-07T00:00:00+02:00","mendeley":null,"updated_at":"1969-12-31T16:00:00-08:00","mas":48037814,"pub_med_central":null,"citations_count":98,"title":"Novel Therapeutic Approach: Ligands for PPAR? and Retinoid Receptors Induce Apoptosis in bcl-2-positive Human Breast Cancer Cells","doi":"10.1023/A:1016114026769","year":2002,"pub_med":null},{"shortdoi":"dpztfz","published":"2000-09-15T00:00:00+02:00","mendeley":null,"updated_at":"1969-12-31T16:00:00-08:00","mas":36366571,"pub_med_central":null,"citations_count":240,"title":"X Inactivation in the Mouse Embryo Deficient for Dnmt1: Distinct Effect of Hypomethylation on Imprinted and Random X Inactivation","doi":"10.1006/dbio.2000.9823","year":2000,"pub_med":null},{"shortdoi":"dpztfz","published":"2000-09-15T00:00:00+02:00","mendeley":null,"updated_at":"1969-12-31T16:00:00-08:00","mas":36366571,"pub_med_central":null,"citations_count":240,"title":"X Inactivation in the Mouse Embryo Deficient for Dnmt1: Distinct Effect of Hypomethylation on Imprinted and Random X Inactivation","doi":"10.1006/dbio.2000.9823","year":2000,"pub_med":null},{"shortdoi":"dm3","published":"1998-08-01T00:00:00+02:00","mendeley":null,"updated_at":"1969-12-31T16:00:00-08:00","mas":36468560,"pub_med_central":null,"citations_count":29,"title":"MSG1(Melanocyte-Specific Gene 1): Mapping to Chromosome Xq13.1, Genomic Organization, and Promoter Analysis","doi":"10.1006/geno.1998.5383","year":1998,"pub_med":"9721210"},{"shortdoi":"dhx","published":"1997-12-19T00:00:00+01:00","mendeley":null,"updated_at":"1969-12-31T16:00:00-08:00","mas":35259662,"pub_med_central":null,"citations_count":70,"title":"MSG1 and its related protein MRG1 share a transcription activating domain","doi":"10.1016/S0378-1119(97)00551-9","year":1997,"pub_med":null},{"shortdoi":"bc8cpk","published":null,"mendeley":null,"updated_at":"1969-12-31T16:00:00-08:00","mas":31740750,"pub_med_central":null,"citations_count":0,"title":"Experimental animal model of hematogenous cardiac metastasis and neoplastic cardiac tamponade","doi":"10.1002/(SICI)1096-9098(199702)64:2<122::AID-JSO6>3.3.CO;2-6","year":1997,"pub_med":null},{"shortdoi":"dm4","published":null,"mendeley":null,"updated_at":"1969-12-31T16:00:00-08:00","mas":31740777,"pub_med_central":null,"citations_count":0,"title":"Experimental animal model of hematogenous cardiac metastasis and neoplastic cardiac tamponade","doi":"10.1002/(SICI)1096-9098(199702)64:2<122::AID-JSO6>3.0.CO;2-D","year":1997,"pub_med":null},{"shortdoi":"dhn","published":null,"mendeley":null,"updated_at":"1969-12-31T16:00:00-08:00","mas":31431247,"pub_med_central":"2647242","citations_count":12,"title":"Hepatic and Serologic Toxicity of Systemic Interleukin-2 and/or Interferon-?","doi":"10.1097/00000421-199406000-00004","year":1994,"pub_med":"18598597"},{"shortdoi":"dh5","published":null,"mendeley":null,"updated_at":"1969-12-31T16:00:00-08:00","mas":31085689,"pub_med_central":null,"citations_count":11,"title":"Lack of therapeutic efficacy of tamoxifen in advanced renal cell carcinoma","doi":"10.1016/S0959-8049(05)80357-0","year":1993,"pub_med":null},{"shortdoi":"dm5","published":null,"mendeley":null,"updated_at":"1969-12-31T16:00:00-08:00","mas":28879588,"pub_med_central":null,"citations_count":5,"title":"Neuropsychiatric symptoms during treatment with interleukin-2 and interferon-?","doi":"10.1016/0140-6736(93)90172-D","year":1993,"pub_med":null}],"citations":[{"source_name":"PLoS","count":0,"source_id":5},{"source_name":"Citeulike","count":9,"source_id":2},{"source_name":"Mendeley","count":3,"source_id":4},{"source_name":"PubMed","count":0,"source_id":1},{"source_name":"Academic Search","count":311,"source_id":3},{"source_name":"CrossRef","count":290,"source_id":7}],"name":"Martin Fenner","mendeley":"martin-fenner","updated_at":"2012-05-17T12:03:33-07:00","location":"Hannover, Germany","website":"http://blogs.plos.org/mfenner","description":"Clinical fellow in oncology and science blogger.","mas":"7086796","works_count":30,"authorclaim":"pfe2"}}